-
Clin Cancer Res: The new BTK inhibitor Zanubrutinib is used to treat relapsed/refractory marginal zone lymphoma
Time of Update: 2021-12-24
Zanubrutinib has shown a high objective remission rate and complete remission rate in patients with relapsed/refractory marginal zone lymphoma, and has a long-lasting disease control effect and good safety .
-
Nature: CLIP1-LTK, a new target for non-small cell lung cancer was discovered, and loratinib works well
Time of Update: 2021-12-24
The transformation activity of CLIP1-LTK fusion in vivo (Source: Nature)Thanks to the above results, looking for kinase inhibitors of CLIP1-LTK protein will have clinical therapeutic significance .
Nature (2021)1 The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
-
Roche's PD-L1+TIGIT dual target is used in the first-line NSCLC treatment, the effect is amazing, and the risk of OS death is reduced by 71%
Time of Update: 2021-12-24
On December 10, Roche announced the latest data on the PD-L1 antibody + TIGIT antibody combined with the first-line treatment of NSCLC Phase II clinical CITYSCAPE .
-
Nat Med: Safety and efficacy of Avapritinib in patients with advanced systemic mastocytosis
Time of Update: 2021-12-24
The primary endpoint of the study is the overall response rate (ORR), and the secondary endpoints include patients with chronic systemic mastocytosis-symptom assessment table total symptom score and average baseline change in quality of life, response time, response duration, and progression-free survival Changes in life, overall survival, disease burden, and safety indicators .
-
Clin Cancer Res: Efficacy of the PARP inhibitor Pamiparib as a single agent in the treatment of platinum-sensitive/resistant ovarian cancer
Time of Update: 2021-12-24
Pamiparib 60 mg bid showed longer-lasting anti-tumor activity in patients with platinum-sensitive ovarian cancer or platinum-resistant ovarian cancer carrying gBRCAmut.
Pamiparib Monotherapy for Patients With Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated With at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study .
-
BJU Int: Should patients with non-muscular invasive bladder cancer stop using fibrin clot inhibitors during BCG?
Time of Update: 2021-12-24
Recently, researchers from the United States published an article in "BJU Int" to determine the impact of FCI on oncology results in a cohort of patients with non-muscular invasive bladder cancer (NMIBC) who received adequate BCG therapy .
-
Cancer Cell: All cancers can be simply divided into two categories, according to whether they express YAP protein
Time of Update: 2021-12-24
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activityThe study shows that all cancers can be divided into two categories based on whether they express YAP protein.
-
What is the impact of the inherent EGFR gene mutation on the targeted therapy of lung cancer?
Time of Update: 2021-12-05
The median progression-free survival time of EGFR-targeted drug therapy is four months, which is much shorter than that of patients without EGFR blast cell mutations .
Some patients used the first-generation EGFR-targeted drug gefitinib in second-line treatment, and the median progression-free survival time was only 8 months .
-
Science Sub-Journal: New anti-cancer mechanism of paclitaxel!
Time of Update: 2021-12-05
04Tumor Life Passage The whole process of real demonstration of internal jugular venous catheter placement is worth collecting!
Long press the QR code to follow us The latest tumor information is waiting for you!
-
Sub-Journal of "Nature": Cancer cells "sneak" on T cells!
Time of Update: 2021-12-05
For the first time, researchers discovered that cancer cells actually "stole" immune cells through nanotube structures between cells.
This is the first time it has been discovered that cancer cells can steal mitochondria from immune cells through nanotubes!
-
Low-level "markers" prompt: better outcomes for advanced kidney cancer
Time of Update: 2021-12-05
This study conducted a retrospective analysis of the results of the first interim analysis of the Phase III JAVELIN Renal 101 study, and evaluated the baseline NLR levels and progression-free survival (PFS) in the avirumumab+axitinib group and the sunitinib group.
-
Express treatment of specific lung cancer patients, Hutchison Medicine and AstraZeneca initiate phase 3 clinical trials of combination therapy in China
Time of Update: 2021-12-05
The trial will be carried out in lung cancer patients with EGFR and MET mutations or abnormalities who have relapsed after receiving EGFR inhibitor treatment, and aims to evaluate highly selective and potent oral mesenchymal transition factor (MET) tyrosine kinase inhibitors (TKI) Orpathys, the efficacy and safety of the combination with AstraZeneca’s third-generation irreversible epidermal growth factor receptor (EGFR) TKI Tagrisso .
-
[Gut Microbes] Why is the "king of cancer" pancreatic cancer so difficult to treat? It turns out that anticancer drugs are secretly eaten by bacteria!
Time of Update: 2021-12-05
Reducing the effects of cytostatics The link between IPMNs and pancreatic cancer is not fully understood, but early studies at the Karolinska Institute and elsewhere have shown that the presence of oral bacteria in the pancreas may be a measure of the severity of IPMN lesions Indicators .
-
Sub-Journal of The Lancet: Is immunotherapy administered during the day or at night?
Time of Update: 2021-12-05
Recently, The Lancet Oncology published a study that the time for melanoma patients to receive immunotherapy has a certain impact on the survival of patients, and PD-1 inhibitors may be best injected before 4:30 in the afternoon [3] .
-
The world's first subcutaneous PD-L1 envolimab is approved for marketing in China
Time of Update: 2021-12-05
Recently, according to the latest announcement by the National Medical Products Administration (NMPA) of China, Corning Jereh, Siddi Medicine, and Simcere Pharmaceuticals have reached a strategic cooperation with Class 1 biological drug Envolimab Injection (KN035) that has been qualified.
-
Will dyeing hair cause cancer? More and more studies have found that the risk of these cancers will increase
Time of Update: 2021-12-05
In 2019, a study published in the International Journal of Cancer found that the use of permanent hair dyes and hair straighteners was associated with an increased risk of breast cancer in women .
-
For the first time in complete remission, Aptevo shows new positive clinical data for targeting CD123xCD3 double antibodies, Yi Mai Meng broke the news
Time of Update: 2021-12-05
APVO436 is a bispecific antibody targeting CD123 and CD3 The candidate product is currently being evaluated for efficacy and safety in the treatment of acute myeloid leukemia (AML) .
-
EMBO J Cancer Review 2021: The molecular, cellular and tissue origins of cancer
Time of Update: 2021-12-05
The EMBO Journal Cancer Review 2021 Welcome to scan the code to read this series of review papers containing articles published in The EMBO Journal in 2021, covering all aspects of tumor biology, including hypoxia, cancer evolution, and the role of metabolism in the tumor microenvironment , Cellular senescence, RNA translation regulation, cell communication through extracellular vesicles, autophagy, etc.
-
Cutting-edge targeting Nobel Prize signaling pathway, the disease control rate of innovative therapies for renal cell carcinoma reached 98%
Time of Update: 2021-12-05
(MSD) for the treatment of patients with renal cell carcinoma associated with von Hippel-Lindau (VHL) disease The results of a phase 2 clinical trial in the New England Journal of Medicine "Released on .
-
Hundred cases of excellent brain metastases from advanced lung cancer-macromolecular anti-angiogenic drugs combined with chemotherapy bring tumor regression
Time of Update: 2021-12-05
Immediately given oral erlotinib (150mg/day) treatment, the headache symptoms disappeared after 1 month, and the imaging review showed that the lung tumor lesions and intracranial metastases were reduced.